Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
So far, the cornerstone therapy of DN consists of renin-angiotensin system (RAS) inhibitors, agents that decrease the synthesis of intrarenal angiotensin II or block its receptors.
|
30961500 |
2020 |
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Attenuation of diabetic nephropathy by dietary fenugreek (Trigonella foenum-graecum) seeds and onion (Allium cepa) via suppression of glucose transporters and renin-angiotensin system.
|
31408826 |
2020 |
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Renin-angiotensin system inhibitors (RASi) are the most effective treatments for diabetic kidney disease but significant residual renal risk remains, possibly because of other mechanisms of kidney disease progression unrelated to RAS that may be present.
|
31742881 |
2020 |
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
To investigate levels and changes in diabetes distress over the course of the PRIORITY (Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In people with TYpe 2 diabetes and normoalbuminuria) randomised controlled trial of screening for diabetic kidney disease (DKD) risk among people with type 2 diabetes (T2D) at a specialist diabetes clinic in Denmark.
|
31676252 |
2020 |
Diabetic Nephropathy
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Diabetic nephropathy (DN) is a diabetes complication that comes from overactivation of Renin-Angiotensin System, excessive pro-inflammatory factors, reactive oxygen species (ROS) overproduction, and potential epigenetic changes.
|
31525975 |
2019 |
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Active renin was increased in urine samples from patients with DKD (n=36), compared with those without DKD (n=38; 3.2 versus 1.3 pg/mg creatinine; P<0.001).
|
31079532 |
2019 |
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Concurrent neprilysin inhibition and renin-angiotensin system modulations prevented diabetic nephropathy.
|
30769114 |
2019 |
Diabetic Nephropathy
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In summary, T2DN rats developed renal and physiological abnormalities similar to clinical observations in human patients with DKD, including progressive glomerular damage and a significant decrease in renin-angiotensin-aldosterone system plasma levels, indicating these rats are an excellent model for studying the progression of renal damage in type 2 DKD.
|
31566426 |
2019 |
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Chronic activation of endocrine systems controlling fluid homeostasis, such as the renin-angiotensin-aldosterone system and vasopressin axis, has a role in progressive kidney desensitisation and diabetic nephropathy.
|
31255583 |
2019 |
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
The intrarenal renin-angiotensin system, in particular augmentation of angiotensinogen (AGT) in proximal tubular cells (PTC), plays a crucial role in the development of diabetic nephropathy.
|
30466736 |
2019 |
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
This review evaluates the effect of paricalcitol in combination with renin-angiotensin-aldosterone system inhibitor therapy in managing DN.
|
31601446 |
2019 |
Diabetic Nephropathy
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
|
30737754 |
2019 |
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Both innate immunity and the renin-angiotensin system (RAS) play important roles in the pathogenesis of diabetic nephropathy (DN).
|
30959575 |
2019 |
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Despite optimal management of diabetic kidney disease (DKD) with intensive glycemic control and administration of agents blocking the renin-angiotensinaldosterone- system, the residual risk for nephropathy progression to end-stage-renal-disease (ESRD) remains high.
|
29792136 |
2019 |
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Vitamin D exerts its pharmacological effects primarily via vitamin D receptor, whose activation inhibits the renin-angiotensin system, a key culprit for DN under hyperglycemia.
|
30287151 |
2019 |
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Increased activity of the intrarenal renin-angiotensin system (RAS) contributes to diabetic nephropathy (DN).
|
31131896 |
2019 |
Diabetic Nephropathy
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
We performed a <i>post-hoc</i> analysis of a double-blind, randomized, crossover trial in patients with type 2 diabetes with early-stage diabetic kidney disease on stable renin-angiotensin-aldosterone system blockade, with an albumin-to-creatinine ratio between 100 and 3500 mg/g, eGFR≥45 ml/min per 1.73 m<sup>2</sup>, and glycosylated hemoglobin≥7.2% and <11.4%.
|
30559106 |
2019 |
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Patients with DN (urinary albumin [UA] >30 mg/g of creatinine) whose estimated glomerular filtration rate (eGFR) was more than 30 mL/min were selected and their plasma renin, parathyroid hormone, serum Vitamin D, serum calcium, serum creatinine, fasting blood sugar were done as baseline measurements.
|
29386413 |
2019 |
Diabetic Nephropathy
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
There is no cure for diabetic nephropathy and the current management of this condition includes glycaemic control, blockade of the renin-angiotensin aldosterone system and lifestyle changes.
|
30257247 |
2019 |
Diabetic Nephropathy
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Depressor arm of the renin-angiotensin system (RAS) exerts reno-protective effects in chronic kidney diseases like diabetic nephropathy.
|
31470003 |
2019 |
Diabetic Nephropathy
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
DKD-related anemia developed earlier and was more severe than non-DKD-related anemia based on more complicated mechanisms, including greater bleeding tendency associated with antiplatelet effect, less O2 sensing due to autonomic neuropathy or renin-angiotensin-aldosterone system inhibitor use, inhibitory effect of inflammatory cytokines, urinary loss of erythropoietin (EPO), and poor response to EPO.
|
31453863 |
2019 |
Diabetic Nephropathy
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In diabetic kidney disease (DKD) increased activation of renin-angiotensin-aldosterone system (RAAS) contributes to renal fibrosis.
|
30324679 |
2019 |
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Imarikiren is a novel, potent, and selective direct renin inhibitor that has shown high oral availability during clinical development for the treatment of diabetic nephropathy.
|
30755452 |
2019 |
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Current therapeutic options, hyperglycemia and blood pressure control, use of a statins and renin-angiotensin-aldosterone blockers, to some extent retard progression, but do not prevent the development of DN.
|
30914013 |
2019 |
Diabetic Nephropathy
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Increasing evidences indicated that the activation of the renin-angiotensin system plays a pivotal role during the progression of diabetic kidney disease.
|
31217864 |
2019 |